References:
Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, Myung JK, et al.(2010). Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 17: 535-546.
Azeem W, Hellem MR, Olsen JR, Hua Y, Marvyin K, Qu Y, et al.(2017). An androgen response element driven reporter assay for the detection of androgen receptor activity in prostate cells. PLoS One 12: e0177861.
Balk SP (2002). Androgen receptor as a target in androgen-independent prostate cancer. Urology 60: 132-138; discussion 138-139.
Beltran H, Yelensky R, Frampton GM, Park K, Downing SR, MacDonald TY, et al. (2013). Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol 63: 920-926.
Bird GH, Lajmi AR, & Shin JA (2002). Sequence-specific recognition of DNA by hydrophobic, alanine-rich mutants of the basic region/leucine zipper motif investigated by fluorescence anisotropy. Biopolymers 65: 10-20.
Caboni L, & Lloyd DG (2013). Beyond the ligand-binding pocket: targeting alternate sites in nuclear receptors. Med Res Rev 33:1081-1118.
Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al.(2004). Molecular determinants of resistance to antiandrogen therapy. Nat Med 10: 33-39.
Claessens F, Denayer S, Van Tilborgh N, Kerkhofs S, Helsen C, & Haelens A (2008). Diverse roles of androgen receptor (AR) domains in AR-mediated signaling. Nucl Recept Signal 6: e008.
Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, et al. (1994). Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54: 5474-5478.
Dalal K, Ban F, Li H, Morin H, Roshan-Moniri M, Tam KJ, et al.(2018). Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer. Cancer Lett 437: 35-43.
Dalal K, Roshan-Moniri M, Sharma A, Li H, Ban F, Hassona MD, et al. (2014). Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer. J Biol Chem 289: 26417-26429.
Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, & Tindall DJ (2008). Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68: 5469-5477.
Denayer S, Helsen C, Thorrez L, Haelens A, & Claessens F (2010). The rules of DNA recognition by the androgen receptor. Mol Endocrinol 24: 898-913.
Deslypere JP, Young M, Wilson JD, & McPhaul MJ (1992). Testosterone and 5 alpha-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene. Mol Cell Endocrinol 88: 15-22.
Duff MR, Jr., Grubbs J, & Howell EE (2011). Isothermal titration calorimetry for measuring macromolecule-ligand affinity. J Vis Exp.
Dupaul-Chicoine J, Yeretssian G, Doiron K, Bergstrom KSB, McIntire CR, LeBlanc PM, et al. (2010). Control of Intestinal Homeostasis, Colitis, and Colitis-Associated Colorectal Cancer by the Inflammatory Caspases. Immunity 32: 367-378.
Fenton MA, Shuster TD, Fertig AM, Taplin ME, Kolvenbag G, Bubley GJ, et al. (1997). Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res 3: 1383-1388.
Gao W, Bohl CE, & Dalton JT (2005). Chemistry and structural biology of androgen receptor. Chem Rev 105: 3352-3370.
Gottlieb B, Beitel LK, Nadarajah A, Paliouras M, & Trifiro M (2012). The androgen receptor gene mutations database: 2012 update. Hum Mutat 33: 887-894.
Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. (2012). The mutational landscape of lethal castration-resistant prostate cancer. Nature 487: 239-243.
Gregory CW, Fei X, Ponguta LA, He B, Bill HM, French FS, et al.(2004). Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. The Journal of biological chemistry 279: 7119-7130.
Guntur AR, & Rosen CJ (2013). IGF-1 regulation of key signaling pathways in bone. Bonekey Rep 2: 437.
Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, et al. (2009). A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 69: 2305-2313.
Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, et al. (2003). Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 63: 149-153.
Hellman LM, & Fried MG (2007). Electrophoretic mobility shift assay (EMSA) for detecting protein-nucleic acid interactions. Nat Protoc 2: 1849-1861.
Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, & Hittmair A (1995). Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 55: 3068-3072.
Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, & Hittmair A (1996). Androgen receptor status of lymph node metastases from prostate cancer. Prostate 28: 129-135.
Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, et al.(2009). Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69: 16-22.
Iwamura M, Sluss PM, Casamento JB, & Cockett AT (1993). Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines. Prostate 22: 243-252.
Kaufman M, & Pinsky L (1983). The dissociation of testosterone- and 5 alpha-dihydrotestosterone-receptor complexes formed within cultured human genital skin fibroblasts. J Steroid Biochem 18: 121-125.
Kim HJ, Park YI, & Dong MS (2006). Comparison of prostate cancer cell lines for androgen receptor-mediated reporter gene assays. Toxicol In Vitro 20: 1159-1167.
Korpal M, Korn JM, Gao X, Rakiec DP, Ruddy DA, Doshi S, et al.(2013). An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov 3: 1030-1043.
Kuiper GG, & Brinkmann AO (1995). Phosphotryptic peptide analysis of the human androgen receptor: detection of a hormone-induced phosphopeptide. Biochemistry 34: 1851-1857.
Lallous N, Dalal K, Cherkasov A, & Rennie PS (2013). Targeting alternative sites on the androgen receptor to treat castration-resistant prostate cancer. Int J Mol Sci 14: 12496-12519.
Lallous N, Volik SV, Awrey S, Leblanc E, Tse R, Murillo J, et al.(2016). Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients. Genome Biol 17: 10.
Li W, Ouyang Z, Zhang Q, Wang L, Shen Y, Wu X, et al. (2014). SBF-1 exerts strong anticervical cancer effect through inducing endoplasmic reticulum stress-associated cell death via targeting sarco/endoplasmic reticulum Ca(2+)-ATPase 2. Cell Death Dis 5:e1581.
Li W, Song R, Fang X, Wang L, Chen W, Tang P, et al. (2012). SBF-1, a synthetic steroidal glycoside, inhibits melanoma growth and metastasis through blocking interaction between PDK1 and AKT3. Biochem Pharmacol 84: 172-181.
Li X, Zhang C, Shi Q, Yang T, Zhu Q, Tian Y, et al. (2013). Improving the efficacy of conventional therapy by adding andrographolide sulfonate in the treatment of severe hand, foot, and mouth disease: a randomized controlled trial. Evidence-based complementary and alternative medicine : eCAM 2013: 316250.
Linja MJ, Savinainen KJ, Saramäki OR, Tammela TL, Vessella RL, & Visakorpi T (2001). Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61: 3550-3555.
McKeehan WL, Adams PS, & Rosser MP (1984). Direct mitogenic effects of insulin, epidermal growth factor, glucocorticoid, cholera toxin, unknown pituitary factors and possibly prolactin, but not androgen, on normal rat prostate epithelial cells in serum-free, primary cell culture. Cancer Res 44: 1998-2010.
Mohler JL, Titus MA, Bai S, Kennerley BJ, Lih FB, Tomer KB, et al. (2011). Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer. Cancer Res 71: 1486-1496.
Paul R, & Breul J (2000). Antiandrogen withdrawal syndrome associated with prostate cancer therapies: incidence and clinical significance. Drug Saf 23: 381-390.
Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. (2015). Integrative clinical genomics of advanced prostate cancer. Cell 161: 1215-1228.
Sadi MV, & Barrack ER (1991). Determination of growth fraction in advanced prostate cancer by Ki-67 immunostaining and its relationship to the time to tumor progression after hormonal therapy. Cancer 67: 3065-3071.
Schaufele F, Carbonell X, Guerbadot M, Borngraeber S, Chapman MS, Ma AAK, et al. (2005). The structural basis of androgen receptor activation: intramolecular and intermolecular amino-carboxy interactions. Proc Natl Acad Sci USA 102: 9802-9807.
Shaffer PL, Jivan A, Dollins DE, Claessens F, & Gewirth DT (2004). Structural basis of androgen receptor binding to selective androgen response elements. Proc Natl Acad Sci USA 101: 4758-4763.
Siegel RL, Miller KD, & Jemal A (2019). Cancer statistics, 2019. CA Cancer J Clin 69: 7-34.
Skala W, Goettig P, & Brandstetter H (2013). Do-it-yourself histidine-tagged bovine enterokinase: a handy member of the protein engineer’s toolbox. J Biotechnol 168: 421-425.
Steinkamp MP, O’Mahony OA, Brogley M, Rehman H, Lapensee EW, Dhanasekaran S, et al. (2009). Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res 69: 4434-4442.
Steketee K, Timmerman L, Ziel-van der Made AC, Doesburg P, Brinkmann AO, & Trapman J (2002). Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer. Int J Cancer 100:309-317.
Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, et al. (2010a). Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 120: 2715-2730.
Sun Y, Wu XX, Yin Y, Gong FY, Shen Y, Cai TT, et al. (2010b). Novel immunomodulatory properties of cirsilineol through selective inhibition of IFN-gamma signaling in a murine model of inflammatory bowel disease. Biochem Pharmacol 79: 229-238.
Tan J, Sharief Y, Hamil KG, Gregory CW, Zang DY, Sar M, et al.(1997). Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 11: 450-459.
Taplin M-E, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, et al. (2003). Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 21: 2673-2678.
Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, et al. (1999). Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59:2511-2515.
Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, et al. (1995). Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332:1393-1398.
Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. (2010). Integrative genomic profiling of human prostate cancer. Cancer Cell 18: 11-22.
Tian X, He Y, & Zhou J (2015). Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistance. Front Pharmacol 6: 57.
Tilley WD, Lim-Tio SS, Horsfall DJ, Aspinall JO, Marshall VR, & Skinner JM (1994). Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: measurement by color video image analysis. Cancer Res 54: 4096-4102.
Tzivion G, Dobson M, & Ramakrishnan G (2011). FoxO transcription factors; Regulation by AKT and 14-3-3 proteins. Biochim Biophys Acta 1813: 1938-1945.
van der Kwast TH, Schalken J, Ruizeveld de Winter JA, van Vroonhoven CC, Mulder E, Boersma W, et al. (1991). Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer 48: 189-193.
Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, et al. (1990). A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173: 534-540.
Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinänen R, Palmberg C, et al. (1995). In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9:401-406.
Wang F, Liu XQ, Li H, Liang KN, Miner JN, Hong M, et al. (2006). Structure of the ligand-binding domain (LBD) of human androgen receptor in complex with a selective modulator LGD2226. Acta Crystallogr Sect F Struct Biol Cryst Commun 62: 1067-1071.
Watson PA, Arora VK, & Sawyers CL (2015). Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer 15: 701-711.
Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, et al. (2010). Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A 107: 16759-16765.
Wienken CJ, Baaske P, Rothbauer U, Braun D, & Duhr S (2010). Protein-binding assays in biological liquids using microscale thermophoresis. Nat Commun 1: 100.
Wong HY, Burghoorn JA, Van Leeuwen M, De Ruiter PE, Schippers E, Blok LJ, et al. (2004). Phosphorylation of androgen receptor isoforms. Biochem J 383: 267-276.
Yoshida T, Kinoshita H, Segawa T, Nakamura E, Inoue T, Shimizu Y, et al. (2005). Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. Cancer Res 65: 9611-9616.
Zhao Y, Tindall DJ, & Huang H (2014). Modulation of androgen receptor by FOXA1 and FOXO1 factors in prostate cancer. Int J Biol Sci 10: 614-619.
Zheng D, Zhu G, Liao S, Yi W, Luo G, He J, et al. (2015). Dysregulation of the PI3K/Akt signaling pathway affects cell cycle and apoptosis of side population cells in nasopharyngeal carcinoma. Oncol Lett 10: 182-188.
Zheng W, Wang H, Zeng Z, Lin J, Little PJ, Srivastava LK, et al.(2012). The possible role of the Akt signaling pathway in schizophrenia. Brain Res 1470: 145-158.
Zhou XE, Suino-Powell K, Ludidi PL, McDonnell DP, & Xu HE (2010). Expression, purification and primary crystallographic study of human androgen receptor in complex with DNA and coactivator motifs. Protein Expr Purif 71: 21-27.
Zhu GC, Yu CY, She L, Tan HL, Li G, Ren SL, et al. (2015). Metadherin regulation of vascular endothelial growth factor expression is dependent upon the PI3K/Akt pathway in squamous cell carcinoma of the head and neck. Medicine (Baltimore) 94: e502.